LAM SOON (HK)(00411) releases interim performance with a net profit attributable to shareholders of HK$176 million, a 6% decrease year-on-year.
South China (Hong Kong) (00411) released its interim results for the six months ending December 31, 2025. The group achieved revenue of HK$2.669 billion, a decrease of 0.45% compared to the same period last year; gross profit of HK$613 million, a decrease of 3%; net profit attributable to shareholders of HK$176 million, a decrease of 6% year-on-year; basic earnings per share of HK$0.75; interim dividend per share of HK$0.15.
LAM SOON (HK)(00411) announced its interim performance for the six months ended December 31, 2025. The group achieved revenue of HK$2.669 billion, a decrease of 0.45% year-on-year; gross profit of HK$613 million, a decrease of 3% year-on-year; net profit attributable to shareholders of HK$176 million, a decrease of 6% year-on-year; basic earnings per share of HK$0.75; and an interim dividend per share of HK$0.15.
The announcement stated that the gross profit margin narrowed by 0.6 percentage points to 3.0%, mainly due to the increase in raw material costs and the impact of targeted price incentive measures, partially offset by favorable wheat bran prices and ongoing cost-saving initiatives.
Related Articles

GF SEC(01776): "26 GFY1" will be listed on the Shenzhen Stock Exchange starting February 26th.

JIUYUAN GENE (02566): JiKeQin's listing application has been accepted by the National Medical Products Administration.

Novo Nordisk A/S Sponsored ADR Class B (NVO.US) invests up to $2.1 billion in partnership with Vivtex, doubling down on the next generation of oral weight loss drugs.
GF SEC(01776): "26 GFY1" will be listed on the Shenzhen Stock Exchange starting February 26th.

JIUYUAN GENE (02566): JiKeQin's listing application has been accepted by the National Medical Products Administration.

Novo Nordisk A/S Sponsored ADR Class B (NVO.US) invests up to $2.1 billion in partnership with Vivtex, doubling down on the next generation of oral weight loss drugs.

RECOMMEND

Robot Concept Hong Kong Stocks Retreat After Spring Gala Rally As 2026 Emerges As Pivotal Year For Mass Production And Commercialization
25/02/2026

Hong Kong IPO Fundraising Surges Tenfold At Start Of Year As 110 A‑Share Companies Queue For Listings
25/02/2026

AI Iteration Risks Surface As Hong Kong Market Diverges; Low‑Valuation, High‑Dividend Legacy Stocks Attract Capital As Safe Havens
25/02/2026


